Prevalence of the Cefazolin Inoculum Effect (CzIE) in Nasal Colonizing
 Methicillin-Susceptible *Staphylococcus aureus* in Patients from Intensive
 Care Units in Colombia and Use of a Modified Rapid Nitrocefin Test for
 Detection

5

Lina P. Carvajal^{a*}, Sandra Rincon^{a*}, Sara I. Gomez-Villegas^b, Juan M. MatizGonzález^a, Karen Ordoñez^c, Alejandra Santamaria^c, Leonardo Ospina-Navarro^d,
Jaime Beltran^d, Fredy Guevara^{e,f}, Yardany R. Mendez^{g,h}, Soraya Salcedoⁱ,
Alexandra Porras^j, Albert Valencia-Moreno^j, Haley Grennia^k, Alexander Deyanov^k,
Rodrigo Baptista^{k,l,m}, Vincent H. Tamⁿ, Diana Panesso^{a,k,l,m}, Truc T. Tran^{k,l,m},
William R. Miller^{k,l,m}, Cesar A. Arias^{k,l,m#}, Jinnethe Reyes^{a#}

- ¹⁴ ^aMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque,
- 15 Bogota, Colombia.
- ¹⁶ ^bBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- ¹⁷ ^cDepartment of Infectious Diseases, ESE Hospital Universitario, San Jorge de
- 18 Pereira, Pereira, Colombia.
- ¹⁹ ^dClinica Colsubsidio Calle 100, Bogota, Colombia.
- ²⁰ ^eServicio de Infectología, Fundación Santafe de Bogota, Bogota, Colombia.
- ¹Clinica Reina Sofia, Colsanitas, Bogota, Colombia.
- ²² ^gGrupo de Investigacion en Epidemiologia Clinica de Colombia (GRECO),
- 23 Universidad Pedagogica y Tecnologica de Colombia, Tunja, Colombia.
- ²⁴ ^hHospital Regional de Duitama, Duitama, Colombia.

¹³ Affiliations

- ²⁵ Organizacion Clinica General del Norte, Barranquilla, Colombia.
- ²⁶ ^JLos Cobos Medical Center, Bogota, Colombia.
- ²⁷ ^kCenter for Infectious Disease, Houston Methodist Research Institute, Houston, TX
- 28 USA
- ²⁹ [']Division of Infectious Diseases and Department of Medicine, Houston Methodist
- 30 Hospital, Houston, TX USA 77030.
- ³¹ ^mDepartment of Medicine, Weill Cornell Medical College, New York, NY.
- 32 "Departament of Pharmacy Practice and Translational Research, University of
- 33 Houston, Houston, Texas, United States.
- 34
- 35 Running title: Cefazolin Inoculum Effect in Colonizing MSSA in the ICU.
- 36
- *Lina P. Carvajal and Sandra Rincon contributed equally to this work. Author order
 was determined alphabetically.
- 39
- 40 #Corresponding authors:
- Jinnethe Reyes, Molecular Genetics and Antimicrobial Resistance Unit,
 Universidad El Bosque, Bogota, Colombia. reyesjinnethe@unbosque.edu.co
- 43 Cesar A. Arias, Division of Infectious Diseases and Department of Medicine,
- 44 Houston Methodist Hospital, Houston and Center for Infectious Disease, Houston
- 45 Methodist Research Institute Houston, TX USA 77030; Department of Medicine,
- 46 Weill Cornell Medical College, New York, NY. <u>caarias@houstonmethodist.org</u>
- 47
- 48

49

50 ABSTRACT

The cefazolin inoculum effect (CzIE) has been associated with poor clinical 51 outcomes in patients with MSSA infections. We aimed to investigate the point 52 prevalence of the CzIE among nasal colonizing MSSA isolates from ICU patients in 53 a multicenter study in Colombia (2019-2023). Patients underwent nasal swabs to 54 55 assess for S. aureus colonization on admission to the ICU and some individuals had follow-up swabs. We performed cefazolin MIC by broth-microdilution using 56 standard and high-inoculum and developed a modified nitrocefin-based rapid test 57 58 to detect the CzIE. Whole genome sequencing was carried out to characterize BlaZ types and allotypes, phylogenomics and Agr-typing. All swabs were subjected 59 to 16S-rRNA metabarcoding sequencing to evaluate microbiome characteristics 60 associated with the CzIE. A total of 352 patients were included; 46/352 (13%) 61 patients were colonized with S. aureus; 22% (10/46) and 78% (36/46) with MRSA 62 and MSSA, respectively. Among 36 patients that contributed with 43 MSSA 63 colonizing isolates, 21/36 (58%) had MSSA exhibiting the CzIE. BlaZ type A and 64 BlaZ-2 were the predominant type and allotype in 56% and 52%, respectively. 65 66 MSSA belonging to CC30 were highly associated with the CzIE and SNP analyses supported transmission of MSSA exhibiting the CzIE among some patients of the 67 same unit. The modified nitrocefin rapid test had 100%, 94.4% and 97.7% 68 69 sensitivity, specificity and accuracy, respectively. We found a high prevalence point prevalence of the CzIE in MSSA colonizing the nares of critically-ill patients in 70 Colombia. A modified rapid test was highly accurate in detecting the CzIE in this 71 72 patient population.

73

74

75 **INTRODUCTION**

Staphylococcus aureus is a human pathogen and a leading cause of community 76 and healthcare-associated infections (HAI). Staphylococcus species (S. aureus 77 and coagulase negative staphylococci [CoNS]) reside in similar ecological niches 78 in the human body, nasal cavity, nasopharynx, skin, and mucous membranes.¹⁻⁴ It 79 is estimated that about 20% (range 12-30%) of the healthy human population is 80 permanently colonized with S. aureus, 30% of which are intermittent carriers 81 (range 16-70%) and 20% are regarded as non-colonized.¹⁻⁴ The current evidence 82 suggests that there is variability in colonization rates due to geographical location 83 and characteristics of the tested populations.¹ 84

85

Colonization by S. aureus is a well-recognized risk factor for the development of 86 subsequent infections, in particular. bacteremia and 87 hospital-associated pneumonia.⁵⁻⁷ At risk patients include those admitted to the ICU, representing a 88 vulnerable group of individuals with major organic dysfunctions, comorbidities and 89 receiving prolonged courses of broad-spectrum antibiotics. For example, nasal 90 colonization with methicillin-resistant S. aureus (MRSA) is a known risk factor for 91 organisms.⁸ developing ventilator-associated pneumonia these 92 due to 93 Furthermore, screening for multidrug-resistant organisms (MDRO) is often performed in these vulnerable patient populations to guide isolation policies and 94 decolonization strategies.9 95

96

Information on the rates of *S. aureus* colonization in patients in the ICU setting in 97 98 developing countries is limited. Olarte et al., reported that in a population of 708 patients from one ICU in Bogota, Colombia, the rate of S. aureus colonization at 99 admission was 25.8% (7.2% for MRSA and 18.5% for MSSA).¹⁰ In a prospective 100 101 Latin-American study that included a cohort of 675 patients enrolled between 2011 and 2014 in hospitals across nine countries of the region, MSSA were responsible 102 for a substantial number (53.7%) of cases of bacteremia.¹¹ Aggregated data from 103 the Colombian National Health Institute indicates that S. aureus is the fourth and 104 third most common pathogens causing hospital-associated and ICU-related 105 infections, respectively.¹² MSSA accounted for 66% of the infections in the 106 Colombian ICUs.¹² 107

108

 β -lactams are the first line therapy for MSSA infections and, with cefazolin 109 frequently being the "go-to" choice in deep-seated infections.¹³ This preference is 110 largely due to its better side effect profile and tolerability, longer half-life, improved 111 adherence, and low costs, and comparable outcomes.¹⁴⁻¹⁶ In addition, cefazolin is 112 113 also the first-choice option for surgical prophylaxis in a variety of surgical interventions including cardiac to orthopedic surgery.¹⁷⁻¹⁸ However, a concern with 114 115 using cefazolin is the presence of the inoculum effect (CzIE). Indeed, the CzIE has 116 been associated with therapeutic failures in patients with MSSA bloodstream infections,^{19,20} and with the progression to chronic osteomyelitis in children.²¹ In 117 Latin-America, a high prevalence of the CzIE among clinical MSSA isolates 118 recovered from invasive infections has been documented.^{22,23} Studies have 119

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24309236; this version posted July 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

documented rates of the CzIE in Colombia ranging from 34% to 63% in bloodstream and osteomyelitis infections, respectively.²³ A more recent study focusing on bloodstream isolates from reported a point prevalence of 40% for the CzIE.²²

124

In this work, we postulated that the prevalence of the CzIE in colonizing MSSA isolates recovered from patients in the ICU would be higher compared to other patient populations, likely due to increased use of antimicrobials (particularly β lactams) in these patients. Thus, we conducted a multicenter study to investigate

the point prevalence of the CzIE among nasal colonizing MSSA isolates from ICU
patients in four different cities in Colombia. Additionally, we tested the ability of a
modified colorimetric test to identify the CzIE in MSSA recovered from ICU
patients.

133

134 MATERIALS AND METHODS

135 Patient enrollment and nasal swab sampling

We performed a prospective observational cohort study that included 352 patients admitted to six adult ICUs in six high complexity-hospitals in Colombia, enrolled between October 2019 to August 2023, (Universidad El Bosque IRB protocol 476-2018). The Human Subjects Review Committee of the participant institutions approved the study. Patients or their authorized representative provided signed consent for participation in the study. Inclusion criteria encompassed adult patients (>18 years old), admitted at ICU, and provided signed consent. Exclusion criteria

encompassed patients from whom samples were not collected upon ICU 143 144 admission (or those from whom samples were obtained >24 hours after admission), and patients diagnosed with COVID-19. Participating centers (affiliated 145 with medical schools and private hospitals) were in Bogota, (3 hospitals; hospitals 146 C, D, E), Pereira (1 hospital; hospital B), Barranguilla (1 hospital; hospital A), and 147 Duitama (1 hospital; hospital G). Two nasal swabs were obtained from the anterior 148 149 nares (one for microbiological screening of multidrug-resistant pathogens (MDRO) and one for microbiome analysis) at 24 hours of admission to the ICU. Samples 150 were taken by trained nurses and physicians, who were members of the 151 152 participating centers. Nasal samples were obtained from both nostrils and taken using swabs placed immediately in AIMES transport media (to collect and preserve 153 the nasal samples for microbiological screening) and DNA/RNA Shield to stabilize 154 nucleic acids for microbiome analyses. These samples were kept at 4°C until they 155 were shipped to the reference laboratory at Universidad El Bosque. MDRO 156 included Carbapenem-Resistant (CR) Klebsiella 157 pathogens pneumoniae. Enterobacterales, Pseudomonas Acinetobacter. Methicillin-Resistant 158 and Staphylococcus Vancomycin-Resistant Enterococcus 159 aureus, and usina 160 chromogenic agar media (CHROMagar-Orientation). Subsequently, a follow-up nasal swab was planned to be collected from the patients before ICU discharge or 161 hospital transfer (day 1 to day 24), unless the patient died during the ICU stay 162 163 before a sample could be taken or if there were personnel were unable to collect the sample. However, only 175 out of 352 patients had follow-up nasal swabs. 164

165

166 Microbiological screening

Nasal swabs were inoculated onto BHI agar and incubated overnight. Then, using 167 a 10 μL calibrated loop, a loopful of bacterial culture was transferred to 5 mL of BHI 168 169 broth that was incubated for 2 hours at 37°C. Serial dilutions of the BHI broth were performed on saline solution. 500 μ L of a 10⁻⁵ dilution was spread onto 170 171 Chromogenic agar media (CHROMagar-Orientation) using a sterile glass spreader 172 and incubated at 37°C for 18 hours. Colonies compatible with S. aureus were recovered and sub-cultured on BHI agar and identified at genus-species level 173 using a multiplex PCR, which also confirmed the presence of the mecA gene.²⁴ 174 Further, oxacillin susceptibility testing was performed using the agar dilution 175 method following CLSI guidelines.²⁵ 176

177

178 Cefazolin high inoculum effect determination

Cefazolin susceptibility testing was performed by broth microdilution using a 179 standard inoculum of 5x10⁵ CFU/mL following CLSI guidelines.²⁶ Additionally, 180 cefazolin MICs were determined using a high bacterial inoculum (5x10⁷ CFU/mL), 181 as previously described,^{22,27} in three biological replicates. Cefazolin concentrations 182 were from 0.03 to 64 mg/L. Reading of the MIC values at high inoculum and 183 interpretation of the results was carried-out by three independent investigators. The 184 CzIE was defined as MIC of ≤ 8 mg/L at standard inoculum and ≥ 16 mg/L at high 185 186 bacterial inoculum.

187

188 Modification of the rapid test protocol to identify MSSA with CzIE

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24309236; this version posted July 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

We used a previously published²⁸ rapid nitrocefin test to identify isolates exhibiting 189 the CzIE with a modification using ampicillin disks (10 μ g; Oxoid) instead of 190 ampicillin solution.²⁹ Briefly, 1 mL of BHI broth (Oxoid) and one disk of ampicillin 191 (10 μ g) were combined in a 2 mL tube, vigorously mixed for at least 30 seconds 192 193 and incubated for 10 min at room temperature. The assay required that the 194 ampicillin disk was completely submerged into the broth. Next, the solution was mixed vigorously for 30 seconds, and the disk was then removed from the broth 195 196 using sterile loop or tweezer, leaving 1 mL solution of BHI broth containing 197 ampicillin ready to use. Colonies from a pure and fresh culture (less than 72 hours) 198 with similar morphological features were selected on BHI agar using a 1-µL calibrated sterile loop. Then, the content of 1 µL loop full of bacterial colonies was 199 resuspended in 1 mL of ampicillin solution followed by vigorous vortexing for 2 min 200 201 and incubated for 10 min at 36±1°C. Subsequently, the bacterial suspension was 202 vortexed again for 2 min. Then, a second incubation of 10 min at 35 ±1°C followed 203 by 2 minutes of vigorous vortexing was performed. Next, the solution was 204 centrifuged at 5,000 rpm for 10 min at room temperature. A volume of 25 µL of the 205 supernatant was transferred into a 0.2-mL tube containing 25 µL of freshly prepared nitrocefin solution (stock concentration 400 µM prepared in phosphate-206 buffered saline [PBS] at 0.1 M, pH 7.0, as previously reported).^{28,29} This process 207 208 ensured that the bacterial cell pellet at the bottom of the tube was not disturbed. 209 Subsequently, the nitrocefin tubes were incubated at room temperature (15 to 25°C, mean of 22°C) and protected from light, followed by visual inspection to 210 monitor color change at 30 min, 1 h, and 2 h. The results were interpreted under 211

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24309236; this version posted July 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

the incident light and compared with controls (see below). A positive result was any 212 213 observed change in color (from yellow to red) between 30 min to 2 h (See Supplemental Material) (Fig.1). Quality control strains ATCC S. aureus 29213 214 (lacking the CzIE and with a negative rapid test) and TX0117 (exhibiting the CzIE 215 216 and with a positive modified rapid test) were included as control strains, as previously described.^{22,28,29} Performance metrics (sensitivity, specificity, and 217 accuracy) of the modified rapid test were compared to MIC determination at high 218 inoculum (gold standard) using MedCalc software. 219

220

221 Whole genome sequencing, assembly, and genomic analysis

Bacterial DNA extraction was carried out on overnight BHI cultures after 222 lysostaphin treatment using a Qiagen Kit. Library preparation was performed using 223 Illumina prepkit, and sequencing was performed on the Illumina platform NextSeq 224 2000. The raw reads obtained from sequencing by Illumina MiSeq were subjected 225 to quality control by FastQC and Trimmomatic.^{30,31} Subsequently, the reads were 226 assembled with SPAdes,³² annotation was performed using PROKKA³³ and the 227 identification of species was verified employing StrainSeeker, KmerFinder and 228 MLST. Sequence Type (ST) and Clonal Complex identification, as well as 229 submission and curation of new STs, was performed on the PubMLST platform. 230

231

Identification of the *blaZ* gene was performed by BLASTn using the sequence from
 the strain *S. aureus* ATCC 29213 extracted with SeqKit³⁴ and translated using
 MEGAX.³⁵ BlaZ typing was carried out taking into account the amino acids at
 positions 128 and 216, corresponding to positions 119 and 207 including the signal

peptide, as we previously described.²² Finally, the assignment of BlaZ allotypes
(unique amino acid sequences in the analyzed genomes) was performed as
previously described using an identity matrix for protein sequence comparison
elaborated with the previously described 29 allotypes.²²

240

The presence of virulence determinants as accessory gene regulator (Agr) was searched using *in silico* PCR,³⁶ and BLASTn based on the sequence of the four reported *agr* loci (I-IV). Additionally, the Panton-Valentine Leukocidin (PVL) encoding genes (*lukS* and *lukF*) were searched by *in silico* PCR,³⁷ and BLASTn using the coding sequences of *lukS* (ABD22441.1) and *lukF* (ABD21112.1) from *Staphylococcus aureus* subsp. *aureus* USA300_FPR3757.

247

248 **Phylogenomic analysis**

Phylogenetic inference of the nasal MSSA genomes was performed using the core 249 genome (orthologous genes present in at least 95% of the genomes) obtained with 250 Roary,³⁸ using a nasal colonizer *S. argenteus* genome as the outgroup recovered 251 in this work. Orthogroups were individually aligned with PRANK,³⁹ and then 252 concatenated to obtain a consensus matrix. The maximum likelihood (ML) tree was 253 built with the consensus matrix in RAxML⁴⁰ using the GTR evolutionary model and 254 a branch support analysis of 1,000 bootstrap replicates. The resulting ML 255 phylogenetic tree was plotted using iTOL.⁴¹ 256

257

258 Library preparation and 16S sequencing

259 Among the 36 patients colonized with MSSA, twenty-three nasal swabs collected 260 at admission to ICU (10 patients colonized by MSSA exhibiting the CzIE and 13 by MSSA lacking the CzIE) were available for microbiome analysis. Total DNA was 261 obtained using DNA easy Blood and Tissue kit (QIAGEN). DNA samples were 262 subjected to bacterial diversity characterization by amplicon sequencing of the 263 hypervariable region V4 of the 16S rRNA.⁴² For the sequencing process, microbial 264 amplicon libraries were built using barcode primers 515-F (5'-GTG CCA GCM GCC 265 GCG GTA A-3') and 806-R (5'-GGA CTA CHV GGG TWT CTA AT-3').⁴³ After 266 sequencing, forward and reverse raw reads were demultiplexed and merged after 267 268 primer removal using bcl2fastgc software (Illumina). The Quantitative Insights into 269 Microbial Ecology (QIIME2) program was used to extract barcodes and primers from the resulting paired-end sequences.44 Then, DADA2 (QIIME2 plugin) was 270 271 used to remove chimera reads and evaluate the guality of the resulting reads with a Q-Score plot to select the minimum length with an average quality \geq 30. In 272 addition, DADA2 was also used to infer amplicon sequence variants (ASV) by 273 clustering all identical sequenced reads, and taxonomic assignment of ASVs was 274 performed using the Silva v132 database.⁴⁵ Finally, a read abundance matrix of the 275 microbial groups identified for each sample, at the phylum or genus level, was 276 generated. 277

278

The resulting matrix was used for the calculation of a Bray-Curtis dissimilarity matrix that was utilized for PCoA analysis using the ordinate and plot_ordination functions. Differences between groups were evaluated by PERMANOVA and ANOSIM analysis using adonis2 and anosim functions, respectively. Furthermore,

283 microbial α -diversity metrics (Shannon and Simpson indexes, and Richness) were 284 calculated with the function estimate richness, using the abundance matrix rarefied per sample to 2000 reads through rarefy even depth function. All 285 functions are contained in the Phyloseg and Vegan R packages.^{46,47} Taxonomic 286 relative abundance matrices were employed to describe general microbiome 287 composition (all phyla/genera are showed, except taxa with a relative abundance < 288 289 0.5%) in CzIE-positive MSSA and CzIE-negative MSSA nasal microbiome groups. In addition, a differential abundance taxa analysis between groups was performed 290 via run lefSe function of the Microbiome Marker R package, using default options 291 (p-value < 0.05 and an LDA > 2 or LDA < -2).⁴⁸ All graphs and statistical 292 comparisons (Mann-Whitney tests) were done using the Graph Pad Prism software 293 v8.0.1. 294

295

296 Core SNPs Analysis

The core genome SNPs of the 43 MSSA nasal isolates was built with kSNP4 (<u>https://sourceforge.net/projects/ksnp/</u>), using a kmer size set to 19, the optimum size estimated by the kSNP4 program Kchooser.⁴⁹ Pairwise core SNP distance matrix was constructed with the core SNPs using the SNP-dist script (<u>https://github.com/tseemann/snp-dists</u>).

302

303 **Data availability.**

The genomes of the Methicillin-Susceptible *Staphylococcus aureus* isolates, and the nasal microbiome sequencing were submitted to the NCBI GenBank database under the BioProject numbers PRJNA1107600 and PRJNA1108236, respectively.

307

308 **RESULTS**

Colonizing MSSA isolates from ICU patients showed a high prevalence of the CzIE.

A total of 352 patients were included in the study from 2019 to 2023. The patients 311 were enrolled in six ICUs located in four different cities of Colombia (Barranguilla, 312 Pereira, Bogota and Duitama). Nasal swabs were obtained from all the 352 313 patients on admission at ICU. Subsequent nasal swabs were collected in 175 314 patients at follow-up (see Materials and Methods). 46/352 (13%) patients included 315 in the study were colonized by S. aureus. Among those with S. aureus 316 317 colonization, 22% (10/46) and 78% (36/46) were colonized by MRSA and MSSA, respectively (Table 1 and Fig. 2). 318

319

Among the 46 patients colonized with S. aureus who had a nasal swab taken at 320 admission, 22 (48%) had an additional nasal swab taken in the follow-up period of 321 time which varied from day 1 to 24 after admission (Fig. 2). A total of 37/46 322 patients (70%) were colonized by S. aureus in the first nasal swab upon admission 323 to the ICU (30 and 7 with MSSA and MRSA, respectively) (Fig. 2). Among the 22 324 patients who underwent a follow up nasal swab, 9 were found to be colonized by S. 325 aureus only in the second swab on days 1 to 24 (colonization was absent upon 326 327 admission to the ICU), suggesting a potential acquisition during the hospital stay or lack of detection in the first swab (Fig. 2). Among the 22 patients, 13 were positive 328 in the first swab and 8 negative in the second swab. Of note, 5 patients were 329 330 colonized on admission and remained colonized on the second swab taken in the

follow up period (only with MSSA) (**Fig. 2**). A total of 53 *Staphylococcus aureus* isolates were found in 46 patients (**Fig. 2**); 39 isolates (73%) recovered in nasal swabs taken on admission, (7 MRSA and 32 MSSA) and 14 (27%) isolates (3 MRSA and 11 MSSA) on follow up swabs (**Table 1 and Fig. 2**).

335

Among 36 patients that contributed 43 MSSA colonizing isolates, 21/36 (58%) had nasal colonization with MSSA exhibiting the CzIE (**Table 2 and Fig. 2**). Of these, 11 patients were colonized on admission to the ICU, 6 patients during the follow-up period only (range of 3 to 24 days) and 4 patients were colonized at admission and remained colonized during the follow-up (range 4 to 7 days) (**Fig. 2**). The CzIE was identified in 25/43 (58%) of nasal colonizing MSSA (geometric mean of cefazolin MIC of 41.07 mg/L, range 16-128 mg/L).

343

A modified rapid nitrocefin test identified the CzIE in nasal colonizing MSSA

isolates with high accuracy

Due to logistic issues to obtain ampicillin powder for the rapid nitrocefin test previously published, we opted to modify the test by using ampicillin discs (10 μ g) for β-lactamase (BlaZ) induction, since such disks are widely available in developing countries (See Supplemental Material).

350

Compared to the gold standard (MICs using high inoculum by broth microdilution), the modified rapid test identified colonizing MSSA isolates with the CzIE with a sensitivity of 100%, specificity of 94.4% and an overall accuracy of 97.7%. Table

S1 shows that the test showed 100% sensitivity with the three common types of class A β -lactamases (Type A, B and C). The specificity was lower (87.5%) in isolates harboring type B β -lactamase. All colonizing MSSA isolates without *blaZ* gene (CzIE negative), were also correctly identified as negative with the modified CzIE test (**Table S1**).

359

Genomic characteristics of nasal colonizing MSSA isolates from ICU.

Whole genome sequencing of the 43 MSSA isolates indicated that 91% (39/43) of the nasal colonizing MSSA isolates carried the *blaZ* gene (**Fig. 3**). Among them, BlaZ type A and type C were identified in 41% (n=16/39), and 36% (n=14/39) of isolates, respectively. BlaZ type B was the less common type, detected in 23% (n=9/39) of MSSA carrying *blaZ*.

366

When analyzing 25 nasal colonizing MSSA isolates that exhibited the CzIE, BlaZ type A was the predominant type in 56% (14/25 isolates), followed by BlaZ type C in 40% (n=10/25). BlaZ-2 was the predominant allotype in 52% (n=13/25). A novel allotype BlaZ-29 (derived from type C BlaZ) was detected in three isolates displaying the CzIE (**Fig. 3**).

372

Among 18 MSSA lacking the CzIE, 14 isolates harbored the *blaZ* gene and type B was the most predominant BlaZ type identified in 57% (8 out of 14) of these genomes. BlaZ-1 (from type C) and BlaZ-7 (from type B) were the most common

allotypes detected in MSSA lacking the CzIE (57%, 4 isolates of each allotype)
(Fig. 3).

378

We identified a high diversity of clonal lineages among 43 nasal colonizing MSSA 379 380 isolates from ICU patients, represented by eight major clades related to the clonal complexes identified (CC1, CC5, CC9, CC15, CC22, CC30, CC45 and CC398) 381 (Fig. 3). The MSSA that exhibited the CzIE (n = 25) clustered into five clonal 382 groups, CC1 (n = 2), CC5 (n = 2), CC15 (n = 4), CC30 (n = 13), and CC45 (n = 4). 383 Notably, CC30 was the predominant lineage identified among MSSA displaying the 384 385 CzIE (52%, 13 out of 25 isolates), with most of the isolates belonged to ST30 (12 386 out 13 CC30 isolates). Of note, all isolates displaying the CzIE and carrying Agr-III, belonged to CC30 and harbored BlaZ type A and allotype BlaZ-2. MSSA lacking 387 the CzIE clustered into six clonal complexes, CC1 (n = 2), CC5 (n = 7), CC9 (n = 1), 388 CC22 (n = 2), CC45 (n = 2), and CC398 (n = 4); CC5 was the most common genetic 389 background, identified in 39% (7 out of 18 of the MSSA without the CzIE), followed 390 by CC398 found in 22% (n=4 isolates). Further, we found that CC9, CC22, and 391 392 CC398 were lineages exclusively detected in MSSA isolates lacking the CzIE (Fig. 393 3).

394

Phylogenomic analyses indicated that the MSSA population was heterogeneous with the absence of geographical or hospital associations with particular clades, except for a clade belonging to CC45 where five out of six MSSA were recovered from the same hospital in the city of Pereira (**Fig. 3**). The most common clonal

cluster (CC) associated with the CzIE was CC30 (n=13/43). A minor clustering of isolates exhibiting the CzIE (n=4) was observed in CC15.

401

Using the genomic data we also analyzed MSSA isolates recovered from the same 402 patient to evaluate genetic relatedness between these isolates and if subsequent 403 isolates acquired or lost the CzIE. A total of 5 patients had MSSA obtained from 404 405 samples taken on day of admission as well as in the follow up time (4 to 7 days). Whereas two patients had two MSSA isolates recovered only in the day of 406 admission (Fig. 4 and Table S2). Among the isolates exhibiting the CzIE and 407 408 recovered from samples taken at different time points, 3 pairs of isolates (6013/6014, 6048/6204, and 7022/7030) (Fig. 4 and Table S2) showed high 409 genomic relatedness with <20 SNPs difference, suggesting the same MSSA strain. 410 In contrast, isolates 6039/6043, and 6441/6461 recovered from two patients at 411 different time points, displayed distinct genomic, phenotypic, and phylogenetic 412 features suggesting that the patients were colonized with different strains. Similarly, 413 MSSA recovered from the same nasal sample on admission in two patients 414 (isolates 6354/6355 and 6773/6774) showed a distinct genotype and a large 415 416 evolutionary distance (Fig. 4), indicating that the patient was colonized with two different unrelated strains of MSSA. Thus, our findings suggest that three patients 417 retained the same colonizing MSSA during their stay in the ICU and two patients 418 419 were colonized by a different strain (Fig. 4 and Table S2). Of note, isolate pairs 6204/6043 and 6441/6354 were recovered from different patients in hospital B. The 420 pairs shared a high degree of genomic similarity (<20 SNPs), suggesting 421

transmission of MSSA exhibiting the CzIE among patients of the same unit (Fig. 4
and Table S2).

424

425 Components of the nasal microbiota in patients colonized by CzIE positive

426 MSSA had not differences.

Using 16S rRNA amplicon sequencing from patients 23 patients (10 colonized by 427 MSSA exhibiting the CzIE and 13 lacking the CzIE), we attempted to identify 428 microbial communities and estimate their diversity and abundance in the context of 429 the CzIE phenotype. At the phylum level, most of the bacterial population (>80%) in 430 both groups consisted of three ASVs (Amplicon Sequence Variants) (Firmicutes, 431 Bacteroidota, and Proteobacteria) (Fig. S1A). In both groups, Firmicutes was the 432 most abundant taxa followed by Proteobacteria in CzIE-positive group and 433 Bacteroidota in the patients with MSSA lacking the CzIE. No statistically significant 434 differences were observed at the taxonomic level. 435

436

At the genus level, we found an abundance of staphylococci (39.4%) and *Bacillus* 437 (3.8%) in the microbiome of patients colonized with MSSA exhibiting the CzIE 438 compared to the patients lacking the CzIE (abundances of 22.9% and 0.04% 439 respectively), Patients colonized with MSSA without the CzIE had a higher 440 abundance of streptococci (3.9 %) and Moraxella (3.2%) compared to patients 441 442 colonized with MSSA showing CzIE (abundances of 1.3 % and 0.06%. respectively) (Fig. S1A) No statistically significant differences were observed for 443 these abundances at genus level. 444

445

446 Also, we found no statistically significant differences in α -diversity between MSSA 447 CzIE(+) and MSSA CzIE(-) colonized patients (Fig. S1B). However, a lower α diversity tendency was observed in the MSSA CzIE(+) group, mainly at the genus 448 level. Likewise, the β -diversity estimated using PCoA plots also indicated that the 449 general bacterial population structure was indistinct between patient groups in both 450 taxonomic levels, with a non-significant PERMANOVA (Phylum, p=0.94; Genus, 451 p=0.24) and ANOSIM (Phylum, p=0.96; Genus, p=0.59) analyses (Fig. S2). A 452 differential abundance analysis using LefSe showed a unique statistically 453 significant enriched genus (Anaerococcus spp.) (p=0.039, LDA score=4.34) in the 454 nasal microbiome of colonized patients with MSSA exhibiting the CzIE (Fig. S1C), 455 456 with a significant major relative abundance in this group of patients.

457 **DISCUSSION**

458 We postulated that antibiotic pressure, particularly the use of broad-spectrum β -

lactam antibiotics may favor the emergence of the CzIE effect in colonizing S. 459 460 aureus. Our findings support our hypothesis, since we found a high point prevalence (58%) of nasal colonization with MSSA exhibiting the CzIE in our 461 multicenter cohort of ICU patients in Colombia. Previous studies^{19,22,23} have shown 462 a high frequency of the CzIE in Colombian MSSA isolates recovered from patients 463 464 with bacteremia and bone and joint infections and our study confirms that this phenotype seems to be prevalent in Colombian S. aureus, although regional 465 466 variability in the frequency of the CzIE have been documented in MSSA isolates recovered from bacteremia.^{19,20,22,23,50-52} Indeed, among the Latin-American 467 countries (a region with high prevalence of this phenotype) Colombia seems to 468

have one of the highest rates of the CzIE in the region for reasons that are not
clear.^{22,23} Data in critically ill and, particularly ICU patients, are scarce and our
findings provide some support that this phenotype can be frequently found among
critically ill patients that experience heavy antibiotic administration.

473

The genomic analyses revealed that nasal colonizing MSSA from ICU patients 474 exhibiting the CzIE possessed similar characteristics as previously documented in 475 MSSA isolates with this phenotype and recovered from invasive infections.^{21,22} 476 Moreover, our findings support the notion that nasal colonization in the ICU is a 477 very dynamic process. Indeed, we found that patients in the ICU are commonly 478 colonized with more than one strain of S. aureus during the course of the ICU stay. 479 In patients who underwent more than one sampling during the ICU stay, we could 480 determine instances in which the patients were colonized with either the same or 481 different strains. Moreover, we were able to isolate at least two different S. aureus 482 strains from the same swab in two patients. Most importantly, our phylogenomic 483 studies provide support of potential transmission of MSSA strains exhibiting the 484 CzIE between different patients in the ICU in the same unit (Fig. 4). 485

486

Our findings also support a clear association of the CzIE with CC30, harboring BlaZ type A, allotype-2 with Agr type III. We have previously documented this association in isolates from bloodstream infections in Latin America and has also been confirmed in isolates from Korean hospitals.⁵²⁻⁵⁴ Of note, in a cohort study of pediatric patients with acute osteomyelitis, MSSA exhibiting the CzIE and possessing Agr-III were associated with progression to chronic osteomyelitis.²¹ Of

interest, alteration of Agr function has been identified in MSSA displaying the 493 CzIE.^{50,54} Indeed. Agr is responsible of a signaling mechanism in response to 494 population density that plays a preponderant role in activation of expression of 495 virulence factors including the repression of cell-wall associated determinants in S. 496 aureus. Furthermore, perturbation in the activity of Agr in S. aureus has been 497 associated with decreased activity of several antibiotics (ie. β -lactams, 498 vancomycin).⁵⁵ Mutations in *agr* were found in MRSA isolates exhibiting reduced 499 vancomycin susceptibility phenotypes (ie, hVISA, VISA).⁵⁵ In addition, upregulation 500 of agr was identified in S. aureus clinical strains under the presence of sub-501 inhibitory concentrations of oxacillin.⁵⁶ Thus, variations in Agr may be associated 502 with the CzIE and this phenotype could also be marker of enhanced virulence in 503 certain genetic backgrounds. 504

505

506 Although no significant differences were seen in the alpha and beta diversity nasal analyses between CzIE-positive and CzIE-negative microbiomes. 507 Anaerococcus spp. were found to be enriched in the CzIE-positive group. Previous 508 509 studies have described Anaerococcus and other genera (Corynebacterium, Finegoldia, Peptoniphilus, Propionibacterium, and Staphylococcus) as typical 510 511 health-associated human upper respiratory tract (URT) bacteria, with a depletion in pathological conditions as chronic rhinosinusitis (CRS).^{57,58} Other studies have 512 shown that anaerobic bacteria, including Anaerococcus are more abundant in 513 middle meatuses of nasal cavities in CRS patients compared to healthy subjects.⁵⁹ 514

515 Thus, the relationship of *Anaerococcus* spp. colonization with MSSA exhibiting the 516 CzIE in the nose needs to be further investigated.

517

The CzIE is difficult to detect in the routine clinical microbiology laboratory. Indeed, 518 519 the cefazolin MICs at high inoculum are cumbersome to perform and interpret. We 520 previously developed a rapid nitrocefin colorimetric test based on the observation 521 that we could detect high activities of BlaZ released to the milieu in strains that exhibit this phenotype.^{28,29} In a validation study that included a large collection of 522 Latin American strains, we found that the test had an overall specificity and 523 sensitivity of 88.9% and 82.5%, respectively.²⁸ However, we found that ampicillin 524 powder (used to prepare a solution to induce *blaZ*) was not widely available and 525 could be expensive in low resource setting laboratories. Thus, we decided to 526 replace the powder by using an ampicillin disk with a period of incubation of 10 min 527 in BHI broth to release enough ampicillin to serve as the inducer solution. Using 528 the isolates recovered from patients in the ICU, we performed an initial validation of 529 the rapid modified nitrocefin test. Compared with the gold standard (cefazolin MICs 530 at high inoculum), the rapid nitrocefin test exhibited an accuracy of 97.7% (100% 531 532 sensitivity and 94% specificity). Moreover, the previous version of the test had issues with isolates that harbored Type C BlaZ. The new modified version of the 533 test seems to perform better for type C enzymes with an accuracy of 100%. Of 534 note both type A and C BlaZ enzymes are highly associated with the CzIE.^{22,23,28} 535 The reasons for this discrepancy are not clear and we are currently performing a 536 large validation study to determine specific metrics of the modified test. 537

538

Our study has several important limitations, as follows: i) we included only six 539 540 participant centers in different cities in Colombia that may not reflect the situation and complexity of ICUs in other regions. Nevertheless, the included centers have 541 different levels of complexity and capabilities; *ii*) the access to clinical information 542 was limited, therefore, the clinical impact of our findings is unknown; iii) we were 543 unable to recover bacterial isolates from patients which developed infections due to 544 545 logistic difficulties in the clinical laboratories of the participanting centers and, iv) microbiome analyses were only performed in representative samples of patients 546 547 colonized with MSSA, since we only were able to sequence and analyze 23 548 samples.

549

In summary, we found a high point prevalence of the CzIE in colonizing MSSA isolates in ICU patients. Our findings suggest that a complex and dynamic process of colonization of MSSA isolates occurs in ICU patients likely influenced by antibiotic and infection control practices with evidence of patient-to patient transmission of CzIE MSSA strains. The clinical relevance of these findings is the subject of subsequent studies.

556

557 Acknowledgments

The authors thank to Maria Jose Cadavid, Camilo Castellar, Laura Ibarra, Catalina Orejuela and Mauricio Uribe from UGRA, Universidad El Bosque for the technical assistance in this study. Also, to Monica Huertas from Universidad Pedagogica y Tecnologica de Colombia for logistical assistance. This work was supported by Ministerio de Ciencia, Tecnologia e Innovación, grant 130880764152, CT 776-2018

to J.R. and Universidad El Bosque, Convocatoria Interna grant PCI 2023-0002 to
J.R. CAA is supported by National Institutes of Health (NIH)/National Institute of
Allergy and Infectious Diseases (NIAID) grants K24AI121296, R01AI134637,
R01AI148342–01, and P01AI152999.

567

568 Author Contributions

Lina P. Carvajal, Conceptualization, Experimental Assays, Formal analysis, 569 Coordination. Writina 570 Methodoloav and Original draft: Sandra Rincon. Conceptualization, Experimental 571 Assays, Formal analysis. Methodology Coordination, Writing and Original draft; Sara I. Gomez-Villegas, Methodology 572 Modification and Experiments; Juan M. Matiz-González, Bioinformatic Analysis; 573 Karen Ordoñez, Patient Enrollment; Alejandra Santamaria, Microbiology Testing in 574 Hospital: Leonardo Ospina and Jaime Beltran. Patient Enrollment: Fredy Guevara. 575 Patient Enrollment; Yardany Mendez, Patient Enrollment; Soraya Salcedo, Patient 576 Enrollment; Alexandra Porras and Albert Valencia, Patient Enrollment; Haley 577 Grennia, Alexander Devanov, Rodrigo Baptista, Sequencing of isolates: Vincent H. 578 Tam, Experimental Assays; Diana Panesso, Experimental Assays and Formal 579 580 Analysis; Truc T. Tran, Experimental Assays and Formal analysis; William R. Miller, Formal Analysis and Review; Cesar A. Arias, Conceptualization, Writing, Review, 581 Editing and Funding acquisition; Jinnethe Reyes, Conceptualization, Writing, 582 583 Review, Editing and Funding acquisition.

584

585 **REFERENCES**

- Piewngam P, Otto M. 2024. *Staphylococcus aureus* colonisation and strategies
 for decolonisation. Lancet Microbe S2666-5247:00040-5.
- 588 2. Sakr A, Brégeon F, Mège JL, Rolain JM, Blin O. 2018. Staphylococcus aureus
- 589 Nasal Colonization: An Update on Mechanisms, Epidemiology, Risk Factors,
- and Subsequent Infections. Front Microbiol 9:2419.
- 3. Peacock SJ, de Silva I, Lowy FD. 2001. What determines nasal carriage of
 Staphylococcus aureus? Trends Microbiol 9:605-10.
- 4. Gosbell IB, van Hal SJ. 2013. *Staphylococcus aureus* colonisation: some
 guestions answered. Lancet Infect Dis 13:380-1.
- 595 5. Fraser TG, Fatica C, Scarpelli M, Arroliga AC, Guzman J, Shrestha NK, Hixson
- E, Rosenblatt M, Gordon SM, Procop GW. 2010. Decrease in *Staphylococcus aureus* colonization and hospital-acquired infection in a medical intensive care
 unit after institution of an active surveillance and decolonization program. Infect
 Control Hosp Epidemiol 31:779-83.
- 6. Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, van Keulen
 PH, Vandenbroucke-Grauls CM, Meester MH, Verbrugh HA. 2004. Risk and
 outcome of nosocomial *Staphylococcus aureus* bacteraemia in nasal carriers
 versus non-carriers. Lancet 364:703-5.
- von Eiff C, Becker K, Machka K, Stammer H, Peters G. 2001. Nasal carriage as
 a source of *Staphylococcus aureus* bacteremia. Study Group. N Engl J Med
 344:11-6.
- 8. Tilahun B, Faust AC, McCorstin P, Ortegon A. 2015. Nasal colonization and
 lower respiratory tract infections with methicillin-resistant *Staphylococcus aureus*. Am J Crit Care 24:8-12.

9. Gu GY, Chen M, Pan JC, Xiong XL. 2023. Risk of multi-drug-resistant organism 610 611 acquisition from prior bed occupants in the intensive care unit: a meta-analysis. J Hosp Infect 139:44-55. 612 10. Olarte NM, Valderrama IA, Reves KR, Garzón MI, Escobar JA, Castro B, 613 614 Vanegas N. 2010. Colonización por Staphylococcus aureus resistente a la meticilina en una unidad de cuidados intensivos de adultos de un hospital 615 616 colombiano: caracterización fenotípica y molecular con detección de un clon de circulación en la comunidad. Biomedica 30:353-61. 617 11. Seas C, Garcia C, Salles MJ, Labarca J, Luna C, Alvarez-Moreno C, Mejía-618 Villatoro C, Zurita J, Guzmán-Blanco M, Rodríguez-Noriega E, Reves J, Arias 619

CA, Carcamo C, Gotuzzo E, Members of the Latin America Working Group on
Bacterial Resistance. 2018. *Staphylococcus aureus* bloodstream infections in
Latin America: results of a multinational prospective cohort study. J Antimicrob
Chemother 73:212–222.

12. Instituto Nacional de Salud. INAS. Vigilancia por whonet en el ambito
 hospitalario.2020.https://www.ins.gov.co/BibliotecaDigital/vigilancia-por-whonet-

de-resistencia-antimicrobiana-en-el-ambito-hospitalario-colombia-2020.pdf

13. Novy E, Martinière H, Roger C. 2023. The Current Status and Future
 Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically III
 Patients. Antibiotics (Basel) 12:681.

14. Pliakos EE, Ziakas PD, Mylonakis E. 2021. The Cost-effectiveness of Cefazolin
Compared with Antistaphylococcal Penicillins for the Treatment of MethicillinSensitive *Staphylococcus aureus* Bacteremia. Open Forum Infectious Diseases
8:ofab476.

15. Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Moine P, Mueller SW. 634 635 2020. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. J 636 Microbiol Immunol Infect 53:321-327. 637 16. Twilla JD, Algrim A, Adams EH, Samarin M, Cummings C, Finch CK. 2020. 638 Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-639 Susceptible Staphylococcus aureus Bacteremia. Am J Med Sci 360:35-41. 640 17. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish 641 DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA, 642 American Society of Health-System Pharmacists (ASHP) Infectious Diseases 643 644 Society of America (IDSA) Surgical Infection Society (SIS) Society for Healthcare Epidemiology of America (SHEA). 2013. Clinical practice guidelines 645

for antimicrobial prophylaxis in surgery. Surg Infect 14:73–156.

18. Calic D, Ariano RE, Arora RC, Grocott HP, Lakowski TM, Lillico R, Zelenitsky
 SA. 2018. Evaluation of cefazolin antimicrobial prophylaxis during cardiac
 surgery with cardiopulmonary bypass. J Antimicrob Chemother 73:768–771.

19. Miller WR, Seas C, Carvajal LP, Diaz L, Echeverri AM, Ferro C, Rios R, Porras

P, Luna C, Gotuzzo E, Munita JM, Nannini E, Carcamo C, Reyes J, Arias CA.

2018. The Cefazolin Inoculum Effect Is Associated with Increased Mortality in
 Methicillin-Susceptible *Staphylococcus aureus* Bacteremia. Open Forum Infect

654 Dis 5:ofy123.

20. Lee S, Song KH, Jung SI, Park WB, Lee SH, Kim YS, Kwak YG, Kim YK, Kiem
SM, Kim HI, Kim ES, Park KH, Kim NJ, Jang HC, Kim HB; Korea INfectious
Diseases (KIND) study group. 2018. Comparative outcomes of cefazolin versus

658 nafcillin for methicillin-susceptible *Staphylococcus aureus* bacteraemia: a

- prospective multicentre cohort study in Korea. Clin Microbiol Infect 24:152-158.
- 21. McNeil JC, Sommer LM, Boyle M, Hogan P, Vallejo JG, Hultén KG, Flores AR,
- 661 Kaplan SL, Fritz S. 2020. Cefazolin Inoculum Effect and Methicillin-Susceptible
- 662 Staphylococcus aureus Osteoarticular Infections in Children. Antimicrob Agents
- 663 Chemother 64:e00703-20.
- 22. Carvajal LP, Rincon S, Echeverri AM, Porras J, Rios R, Ordoñez KM, Seas C,
- Gomez-Villegas SI, Diaz L, Arias CA, Reyes J. 2020. Novel Insights into the
 Classification of Staphylococcal β-Lactamases in Relation to the Cefazolin
 Inoculum Effect. Antimicrob Agents Chemother 64:e02511-19.
- 23. Rincon S, Reyes J, Carvajal LP, Rojas N, Cortés F, Panesso D, Guzmán M,
 Zurita J, Adachi JA, Murray BE, Nannini EC, Arias CA. 2013. Cefazolin highinoculum effect in methicillin-susceptible *Staphylococcus aureus* from South
 American hospitals. J Antimicrob Chemother 68:2773-8.
- 24. Martineau F, Picard FJ, Lansac N, Ménard C, Roy PH, Ouellette M, Bergeron
 MG. 2000. Correlation between the resistance genotype determined by
 multiplex PCR assays and the antibiotic susceptibility patterns of *Staphylococcus aureus* and *Staphylococcus epidermidis*. Antimicrob Agents
 Chemother 44:231-8.
- 677 25. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 33rd
 678 ed.Wayne PA: CLSI supplement M100; 2023.
- 26. Clinical and Laboratory Standards Institute CLSI, Performance Standards for
 Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement
 M100-S21, 2012. Wayne, PA, USA.

27. Bourreau A, Le Mabecque V, Broquet A, Caillon J. 2023. Prevalence of a
cefazolin inoculum effect associated with *blaZ* gene types, and clinical
outcomes among methicillin-susceptible *Staphylococcus aureus* blood isolates
of patients with infective endocarditis. Infect Dis Now 53:104626.

- 28. Rincon S, Carvajal LP, Gomez-Villegas SI, Echeverri AM, Rios R, Dinh A,
- 687 Pedroza C, Ordoñez KM, Nannini E, Sun Z, Fowler VG, Murray BE, Miller WR,
- Palzkill T, Diaz L, Arias CA, Reyes J. 2021. A Test for the Rapid Detection of the
- Cefazolin Inoculum Effect in Methicillin-Susceptible *Staphylococcus aureus*. J
 Clin Microbiol 59: e01938-20.
- 29. Gomez-Villegas SI, Panesso D, Singh K, Rincon S, Carvajal LP, Jacques-Palaz
- 692 K, Rizvi S, Burnham CA, Abbott A, Dien Bard J, Westblade L, Fritz SA, Zimmer
- B, Dingle TC, Butler-Wu S, Miller WR, Reves J, Arias CA. 2023. Optimization of
- a Nitrocefin-Based Rapid Test for the Detection of the Cefazolin Inoculum Effect
- (CzIE) in Methicillin-Susceptible *Staphylococcus aureus*. Open Forum
 Infectious Diseases 10:ofad500.644.
- 30. Leggett RM, Ramirez-Gonzalez RH, Clavijo BJ, Waite D, Davey RP. 2013.
 Sequencing quality assessment tools to enable data-driven informatics for high
 throughput genomics. Front Genet 4:288.
- 31. Bolger AM, Lohse M, and Usadel B. 2014. "Trimmomatic: A flexible trimmer for
 Illumina sequence data. Bioinformatics 30:2114–2120.
- 32. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin
 VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N,
 Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly

- algorithm and its applications to single-cell sequencing. J Comput Biol 19:455-706 77.
- 707 33. Weemann T. 2014. Prokka: rapid prokaryotic genome annotation.
 708 Bioinformatics 30:2068-9.
- 34. Shen W, Le S, Li Y, Hu F. 2016. SeqKit: A Cross-Platform and Ultrafast Toolkit
- for FASTA/Q File Manipulation. PLoS One 11:e0163962.
- 711 35. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. 2018. MEGA X: Molecular
- Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol.
 35:1547-1549.
- 36. Strommenger B, Cuny C, Werner G, Witte W. 2004. Obvious lack of association
 between dynamics of epidemic methicillin-resistant *Staphylococcus aureus* in
 central Europe and *agr* specificity groups. Eur J Clin Microbiol Infect Dis 23:159.
- 37. Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V,
 Vandenesch F, Etienne J. 1999. Involvement of Panton-Valentine leukocidinproducing *Staphylococcus aureus* in primary skin infections and pneumonia.
 Clin Infect Dis 29:1128-32.
- 38. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M,
 Falush D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan
 genome analysis. Bioinformatics 31:3691-3.
- 39. Löytynoja A. 2014. Phylogeny-aware alignment with PRANK. Methods Mol Biol
 1079:155-70.
- 40. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and
 post-analysis of large phylogenies. Bioinformatics 30:1312-3.

729	41. Letunic I, Bork P. 2021. Interactive Tree of Life (iTOL) v5: an online tool for
730	phylogenetic tree display and annotation. Nucleic Acids Res 49:W293-W296.
731	42. Sadowsky MJ, Staley C, Heiner C, Hall R, Kelly CR, Brandt L, & Khoruts A.
732	2017. Analysis of gut microbiota - An ever changing landscape. Gut Microbes
733	8:268-275.
734	43. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA,
735	Turnbaugh PJ, Fierer N, & Knight R. 2011. Global patterns of 16S rRNA
736	diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U
737	S A 108:4516-22.
738	44.Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA. 2019.
739	Reproducible, interactive, scalable and extensible microbiome data science
740	using QIIME 2. Nat Biotechnol 37:852-857.
741	45. Yilmaz P, Parfrey LW, Yarza P, Gerken J, Pruesse E, Quast C, Schweer T,
742	Peplies J, Ludwig W, Glöckner FO. 2014. The SILVA and "All-species Living
743	Tree Project (LTP)" taxonomic frameworks. Nucleic Acids Res 42:D643-8.
744	46. Dixon, P. 2003. VEGAN, a package of R functions for community ecology.
745	Journal of Vegetation Science 14:927–930.
746	47. McMurdie PJ, & Holmes S. 2013. phyloseq: An R Package for Reproducible
747	Interactive Analysis and Graphics of Microbiome Census Data. Plos One 8: 1-
748	11.
749	48. Cao Y, Dong Q, Wang D, Zhang P, Liu Y, & Niu C. 2022. microbiomeMarker: an
750	R/Bioconductor package for microbiome marker identification and visualization.
751	Bioinformatics 38:4027-4029.

49. Hall BG and Nisbet J. 2023. "Building Phylogenetic Trees from Genome
 Sequences With kSNP4" Mol Biol Evol 40:msad235.

50. Lee SO, Lee S, Park S, Lee JE, Lee SH. 2019. The Cefazolin Inoculum Effect

and the Presence of type A *blaZ* Gene according to *agr* Genotype in Methicillin-

- 756 Susceptible *Staphylococcus aureus* Bacteremia. Infect Chemother 51:376-385.
- 51. Wang SK, Gilchrist A, Loukitcheva A, Plotkin BJ, Sigar IM, Gross AE, O'Donnell
- JN, Pettit N, Buros A, O'Driscoll T, Rhodes NJ, Bethel C, Segreti J, Charnot-

759 Katsikas A, Singh K, Scheetz MH. 2018. Prevalence of a Cefazolin Inoculum

760 Effect Associated with *blaZ* Gene Types among Methicillin-Susceptible

761 Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago.

Antimicrob Agents Chemother 62:e00382-18.

52. Chong YP, Park SJ, Kim ES, Bang KM, Kim MN, Kim SH, Lee SO, Choi SH,

Jeong JY, Woo JH, Kim YS. 2015. Prevalence of *blaZ* gene types and the

cefazolin inoculum effect among methicillin-susceptible *Staphylococcus aureus*

blood isolates and their association with multilocus sequence types and clinical

outcome. Eur J Clin Microbiol Infect Dis 34:349-55.

53. Svishchuk J, Ebbert K, Waddell B, Izydorczyk C, Acosta N, Somayaji R, Rabin

HR, Bjornson CL, Lisboa L, Gregson DB, Conly JM, Surette MG, Parkins MD.

2023. Epidemiology and impact of methicillin-sensitive *Staphylococcus aureus*

- with β -lactam antibiotic inoculum effects in adults with cystic fibrosis. Antimicrob
- Agents Chemother 67:e00136-23.

54. Wi YM, Park YK, Moon C, Ryu SY, Lee H, Ki HK, Cheong HS, Son JS, Lee JS,
Kwon KT, Kim JM, Ha YE, Kang CI, Ko KS, Chung DR, Peck KR, Song JH.
2015. The cefazolin inoculum effect in methicillin-susceptible *Staphylococcus*

- *aureus* blood isolates: their association with dysfunctional accessory gene regulator (*agr*). Diagn Microbiol Infect Dis 83:286-91.
- 55. Singh R, Ray P. 2014. Quorum sensing-mediated regulation of staphylococcal
 virulence and antibiotic resistance. Future Microbiol 9:669-81.
- 56. Viedma E, Pérez-Montarelo D, Villa J, Muñoz-Gallego I, Larrosa N, Fernández-
- Hidalgo N, Gavaldà J, Almirante B, Chaves F. 2018. Sub-inhibitory
 concentrations of oxacillin modify the expression of *agr* locus in *Staphylococcus aureus* clinical strains belonging to different clonal complexes. BMC Infect Dis
- 784 18:177.
- 57. Hoggard M, Biswas K, Zoing M, Wagner-Mackenzie B, Taylor MW, and Douglas
- RG. 2017. Evidence of microbiota dysbiosis in chronic rhinosinusitis. Int ForumAllergy Rhinol 7:230-239.
- 58. Wagner-Mackenzie B, Waite DW, Hoggard M, Douglas RG, Taylor MW, and
- Biswas K. 2017. Bacterial community collapse: a meta-analysis of the sinonasal
- microbiota in chronic rhinosinusitis. Environ Microbiol 19:381–392.
- 59. Copeland E, Leonard K, Carney R, Kong J, Forer M, Naidoo Y, Oliver BGG,
- 792 Seymour JR, Woodcock S, Burke CM, Stow NW. 2018. Chronic Rhinosinusitis:
- 793 Potential Role of Microbial Dysbiosis and Recommendations for Sampling
- 794 Sites. Front Cell Infect Microbiol 8:57.

Table 1. Distribution of S. aureus isolates recovered from 46 patients on admission and follow-up by hospital.

	Methicillin-su	n-susceptible <i>S. aureus</i> (MSSA)	eus (MSSA)	Methicillin-re	Methicillin-resistant S. aureus (MRSA)	<i>ıs</i> (MRSA)
rospital (No patients)	No of patients (No isolates)	No isolates at admission	No isolates at follow-up	No of patients (No isolates)	No isolates at admission	No isolates at follow-up
A (5)	3 (3)	-	N	2 (2)	0	0
B (15)	12 (17)	11	9	3 (3)	÷	N
C (4)	3 (3)	с	0	1 (1)	F	0
D (14)	11 (11)	6	0	3 (3)	က	0
E (3)	3 (4)	4	0	0 (0)	0	0
G (5)	4 (5)	4		1 (1)	0	
Total (46)	36 (43)	32	11	10 (10)	7	က

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24309236; this version posted July 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Hospital	No of MSSA isolates	No of isolates (%) with CzIE	No of isolates (%) without CzIE
Α	3	3 (100)	0 (0)
В	17	10 (59)	7 (41)
С	3	1 (33)	2 (67)
D	11	4 (36)	7 (64)
E	4	3 (75)	1 (25)
G	5	4 (80)	1 (20)
Total	43	25 (58)	18 (42)

Table 2. Distribution of the frequency of the CzIE in colonizing MSSA recovered from ICU patients in 6 Colombian hospitals by gold standard testing.






Fig. 1. Modified protocol of the nitrocefin rapid test to identify MSSA with the CzIE.




No MSSA/MRSA

Fig. 2. Timeline of sampling and isolate recovery in ICU patients colonized by *S. aureus* (MSSA or MRSA). Sampling is denoted by circles; filled circles represent nasal swabs positive for MSSA (red) or MRSA (blue); empty circles indicate samples negative for *S. aureus*. Circles with lines across indicate isolates positive for the CzIE. Patient B74-046 and E76-005 had two isolates recovered in the same swab, one displaying the CzIE and the other lacking the CzIE.



Colored shadows over the tree branches show the clonal complexes (CC) within the sample, followed by Fig. 3. Phylogenetic tree of colonizing methicillin-susceptible S. aureus (MSSA) isolates recovered from ICU patients in Colombian hospitals. Maximum likelihood phylogenetic tree from the core genome (1939 genes) of 43 MSSA and one S. argenteus isolate (outgroup). Support bootstrap values are showed for each clade. Sequence Type (ST) and *agr* type. The CzHI was determined by gold standard (CFZ MIC)

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24309236; this version posted July 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



Patient ID	Isolate ID (Sample Day)	6013	6014	6039	6043	6048	6204	6355	6354	6441	6461	6773	6774	7022	7030
011 012	6013 (0)	0	9	11883	11552	11552	11552	11945	176	179	11997	11925	11834	12006	11998
D/4-UIZ	6014 (7)	9	0	11889	11557	11557	11557	11951	182	185	12003	11931	11840	12012	12003
D74.047	(0) 6209	11883	11889	0	12967	12967	12967	8093	11883	11885	8086	8077	8032	8100	8088
D/4-01/	6043 (7)	11552	11557	12967	0	0	0	12995	11544	11546	12954	12977	12837	12963	12952
010	6048 (0)	11552	11557	12967	0	0	0	12995	11544	11546	12954	12977	12837	12963	12952
D/4-010	6204 (6)	11552	11557	12967	0	0	0	12995	11544	11546	12954	12977	12837	12963	12952
974 046	6355 (0)	11945	11951	8093	12995	12995	12995	0	11948	11949	4394	94	4129	4410	4397
0/4-040	6354 (0)	176	182	11883	11544	11544	11544	11948	0	4	11994	11928	11837	12009	12001
D71 050	6441 (0)	179	185	11885	11546	11546	11546	11949	4	0	11995	11929	11838	12010	12002
P(-+10	6461 (6)	11997	12003	8086	12954	12954	12954	4394	11994	11995	0	4373	4216	190	176
E76 006	6773 (0)	11925	11931	8077	12977	12977	12977	94	11928	11929	4373	0	4107	4388	4375
c00-0/3	6774 (0)	11834	11840	8032	12837	12837	12837	4129	11837	11838	4216	4107	0	4230	4216
C70 011	7022 (0)	12006	12012	8100	12963	12963	12963	4410	12009	12010	190	4388	4230	0	17
410-010	7030 (4)	11998	12003	8088	12952	12952	12952	4397	12001	12002	176	4375	4216	17	0

MSSA pairs are indicated by white blocks and MSSA isolates with CzIE in red. Cells are colored according to SNPs count between two MSSA: Green, MSSA genomes with < 20 SNPs difference; yellow to orange scale, MSSA genomes with ≥ 20 SNPs likely Fig. 4. Count matrix of the core SNPs among colonizing MSSA isolates. Core SNPs of the 43 MSSA analyzed (30927 SNPs). representing a different strain. Day 0 correspond to admission sampling.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24309236; this version posted July 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.